UNSPSC 51101662: Halofuginone

This classification denotes an angiogenesis activator inhibitor and alkaloid with the molecular formula C16H17BrClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L31MM1385E, chemically known as 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, trans- but generally known as halofuginone, which bears US NIH Compound Identifier 62891. European Medicines Agency schedules Halofuginone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08000MIG.

UNSPSC 51101662 Halofuginone is a Commodity code identifying a specific pharmaceutical active ingredient, but the recent state and local contract activity tagged under it involves procurement of finished pharmaceutical products and medical supplies rather than halofuginone itself. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC on August 28, 2026 for supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets under an Invitation for Bid process. Seminole County, Florida also solicited through competitive bidding for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building. The code's nominal scope—halofuginone as an anticoccidial veterinary or poultry-health agent—does not align with the pharmaceutical and public-health products state and local governments are actually purchasing under this classification.

Recent activity centers on state health departments and county public-health agencies procuring finished pharmaceuticals and harm-reduction supplies for emergency response and disease prevention programs. The Illinois Department of Public Health contract was awarded to a single vendor (Chartwell Rx LLC) for a 12-month initial term with two renewal options. Seminole County's procurement in Florida required vendors to meet E-Verify compliance, drug-free workplace certification, and insurance requirements including workers' compensation and professional liability coverage, with potential FEMA funding introducing federal compliance obligations. The code shows limited alignment between its nominal designation and actual procurement activity, suggesting either a classification mismatch in the state and local procurement systems or a departure from the code's original pharmaceutical taxonomy scope. Firms pursuing opportunities under this code should verify the actual product or service specification in each solicitation rather than relying on the code name alone.